Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

JP-1366

Phase 3Small molecule

OOnconic Therapeutics Inc.

JP-1366 is one of 51 small molecule programs targeting Atorvastatin. It is currently in Phase 3.

3

Indications

10

Total Trials

3

Active Trials

50

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtorvastatinRecruiting

Gastroesophageal Reflux DiseaseNot yet recruiting

Peptic UlcerRecruiting

AtorvastatinPhase 1

Recruiting

Gastroesophageal Reflux DiseasePhase 3

Not yet recruiting

Peptic UlcerPhase 3

Recruiting

Competition

Competitive Landscape

28 competitors in Peptic Ulcer

#DrugCompanyPhaseTrials

Prevacid

Nexium

DDexcel Pharma Technologies Ltd.

Bayer Aspirin

Protonix

WWyeth-Lederle Vaccines

Dexilant

Cytotec

Takecab

PPhathom Pharmaceuticals, Inc.

Aciphex

Akero Therapeutics

Rayos

RRoxane Laboratories

Decadron

AAspen Global Incorporated

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Peptic Ulcer

NCT06439563

Q4 2028

Phase 3Not yet recruiting

Gastroesophageal Reflux Disease

NCT07732075

Clinical

Trials by Indication[1]

Gastroesophageal Reflux Disease2 trials

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

Completed·OOnconic Therapeutics Inc.·Phase 2·NCT04282954·188 enrolled

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority Phase 3 Study to Evaluate the Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis

Not yet recruiting·OOnconic Therapeutics Inc.·Phase 3·NCT07732075·384 enrolled

Clinical Trial2 trials

Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Completed·OOnconic Therapeutics Inc.·Phase 1·NCT05712681·24 enrolled

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Completed·OOnconic Therapeutics Inc.·Phase 1·NCT05814809·30 enrolled

Phase 11 trial

Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

Completed·OOnconic Therapeutics Inc.·Phase 1·NCT07181538·55 enrolled

Atorvastatin1 trial

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Recruiting·OOnconic Therapeutics Inc.·Phase 1·NCT07265466·96 enrolled

Drug Interactions1 trial

Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

Completed·OOnconic Therapeutics Inc.·Phase 1·NCT05194046·29 enrolled

3 more indications

Esophagitis1 trial

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Completed·OOnconic Therapeutics Inc.·Phase 3·NCT05443984·300 enrolled

Gastric Ulcer1 trial

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Completed·OOnconic Therapeutics Inc.·Phase 3·NCT05448001·329 enrolled

Peptic ulcer1 trial

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Recruiting·OOnconic Therapeutics Inc.·Phase 3·NCT06439563·364 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for JP-1366. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JP-1366 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JP-1366. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Onconic Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOnconic Therapeutics Inc.

Related News